Drugs Containing Excipient (Inactive Ingredient) APROTININ

« Back to Dashboard

Generic drugs containing APROTININ excipient

Company	Ingredient	NDC	Excipient
Baxter Healthcare Corporation	fibrinogen human, human thrombin	0338-8503	APROTININ

Aprotinin Market Dynamics and Financial Trajectory: Regulatory Risk, Commercial Position, and IP Outlook

Last updated: September 15, 2026

Aprotinin is not a pharmaceutical excipient. It is a biologically derived serine-protease inhibitor and active pharmaceutical ingredient formerly marketed primarily as Trasylol for reducing perioperative blood loss during coronary artery bypass grafting. Its commercial trajectory was shaped by safety concerns, market withdrawal, restricted reintroduction in Europe, and competition from tranexamic acid. Public financial data for aprotinin as a standalone product or ingredient are limited. The market is niche, hospital-based, and highly sensitive to regulatory restrictions and procurement decisions.

What is aprotinin and is it an excipient?

Aprotinin is a polypeptide derived historically from bovine lung or bovine pancreatic tissue. It inhibits several proteases, including plasmin, kallikrein, and trypsin. Its principal pharmaceutical use was as an antifibrinolytic during cardiac surgery involving cardiopulmonary bypass.

Attribute	Aprotinin profile
Substance type	Active pharmaceutical ingredient
Pharmacologic class	Serine-protease inhibitor; antifibrinolytic
Historical brand	Trasylol
Former primary indication	Reduction of perioperative blood loss and transfusion in CABG surgery
Biological source	Historically bovine tissue
Administration	Intravenous
Primary customer	Hospitals and cardiac-surgery centers
Excipient status	Not generally classified as an excipient
Main substitutes	Tranexamic acid and epsilon-aminocaproic acid
Commercial model	Institutional procurement rather than retail pharmacy

An excipient is an inactive component used to formulate, stabilize, preserve, or deliver a drug. Aprotinin has direct pharmacologic activity and is therefore treated as an active drug substance, not a conventional excipient.

How did aprotinin’s commercial trajectory develop?

Aprotinin achieved substantial hospital use in cardiac surgery because it reduced bleeding and blood-product requirements. Its commercial position weakened after observational studies associated the product with renal dysfunction, myocardial infarction, stroke, and mortality risks.

The principal market milestones were:

Period	Commercial and regulatory event
1990s	Aprotinin gained regulatory approval for use in cardiac surgery and became a major antifibrinolytic product
2006	The BART trial reported safety concerns relative to lysine analogues
November 2007	Bayer suspended worldwide marketing of Trasylol after regulatory review
2011-2012	European regulators supported restricted reintroduction under controlled conditions
2010s	Use remained concentrated in selected cardiac-surgery settings
Current market profile	Niche institutional product with limited public revenue disclosure and substantial substitution pressure

The 2008 BART trial found that aprotinin was associated with higher mortality than tranexamic acid and aminocaproic acid in high-risk cardiac surgery. Regulators responded by restricting or suspending use in multiple jurisdictions. The European Medicines Agency later permitted restricted use after a benefit-risk reassessment, subject to controlled prescribing and monitoring requirements. [1][2]

What is the current FDA regulatory status of aprotinin?

Aprotinin’s U.S. regulatory history is defined by the 2007 market suspension and subsequent restrictions. The product was approved for reducing perioperative blood loss and transfusion requirements in patients undergoing cardiopulmonary bypass during CABG surgery.

The FDA’s historical action did not reflect a routine commercial discontinuation. It followed safety signals involving renal failure and cardiovascular and cerebrovascular events. Any current U.S. commercial availability depends on the status of the applicable product, sponsor, labeling, and supply authorization. Aprotinin should therefore be treated as a highly restricted hospital product rather than as a broadly available antifibrinolytic.

In Europe, the product was reintroduced under conditions limiting use to adult patients undergoing isolated primary CABG surgery who are at high risk of major blood loss and who have no alternative treatment option. National implementation and local hospital formularies remain important to actual utilization. [1]

What are the main market drivers for aprotinin?

Aprotinin demand depends on cardiac-surgery volume, transfusion-avoidance policies, blood-product costs, and physician tolerance for safety restrictions.

Cardiac-surgery volume

The addressable market is tied to open-heart surgery involving cardiopulmonary bypass. Aprotinin has little relevance to outpatient surgery, general hospital bleeding management, or chronic treatment.

A decline in open cardiac procedures, minimally invasive techniques, and improved blood-conservation protocols limits volume growth. Aging populations and continued demand for complex cardiac procedures support a residual market, but they do not offset the product’s narrow indication.

Blood-management economics

Aprotinin can reduce bleeding and transfusion requirements, but its acquisition price is only one component of the economic decision. Hospitals also consider:

• acute kidney injury;
• intensive-care utilization;
• dialysis risk;
• transfusion costs;
• operating-room time;
• inventory management;
• regulatory compliance.

The economic case is strongest in patients with expected high blood loss or where blood products are difficult to obtain. The case is weaker when low-cost tranexamic acid provides adequate hemostatic control.

Safety and institutional policy

Safety concerns remain the largest commercial constraint. Hospitals often require specialist approval, renal-risk assessment, documented indication, and postoperative monitoring. These controls reduce casual or routine use.

How does aprotinin compare with tranexamic acid and aminocaproic acid?

Aprotinin competes primarily against lysine analogues, not against other biologic products.

Factor	Aprotinin	Tranexamic acid	Aminocaproic acid
Mechanism	Broad serine-protease inhibition	Plasminogen activation inhibition	Plasminogen activation inhibition
Main cardiac-surgery role	Antifibrinolytic	Antifibrinolytic	Antifibrinolytic
Cost position	Historically higher	Generally low	Generally low
Safety perception	Constrained by renal and cardiovascular concerns	More favorable overall	More favorable overall
Supply model	Specialty hospital product	Broad generic supply	Generic hospital supply
Market trend	Niche and restricted	Standard or preferred option in many settings	Alternative option
Competitive strength	Potential efficacy in selected high-risk cases	Strong formulary position	Secondary alternative

The market has shifted toward tranexamic acid because it is inexpensive, widely available, easier to procure, and supported by broad clinical use. Aprotinin retains a potential role where clinicians value its pharmacologic profile and judge the patient’s bleeding risk to outweigh the product’s safety concerns.

What is the financial trajectory of aprotinin?

Aprotinin’s financial trajectory follows a sharp decline from a significant branded hospital product to a limited specialty market.

Pre-withdrawal period

Before the 2007 suspension, Trasylol generated substantial revenue for Bayer. Public reporting characterized the product as a major hospital brand, with annual sales historically reaching the hundreds of millions of dollars or euros depending on the reporting period and currency basis. It was one of Bayer’s commercially important pharmaceutical products before safety concerns materially changed its position. [3]

Post-2007 period

The suspension removed most conventional branded revenue. Bayer faced the loss of product sales, litigation exposure, regulatory costs, and reputational damage. The commercial impact extended beyond direct revenue because aprotinin’s withdrawal enabled tranexamic acid and aminocaproic acid to capture formulary share.

Restricted reintroduction

Reintroduction in Europe created a residual revenue opportunity but not a return to the prior market structure. The restricted label, narrow patient population, monitoring requirements, and physician reluctance limited volume. Public companies generally do not report aprotinin revenue as a distinct segment, making current market-size estimates unreliable.

Current financial profile

Aprotinin should be valued as a low-volume, high-regulatory-friction hospital medicine. Revenue potential is constrained by:

1. a narrow cardiac-surgery indication;
2. generic substitution;
3. safety-related prescribing controls;
4. limited promotional flexibility;
5. procurement concentration;
6. uncertain supply continuity;
7. lack of a broad outpatient market.

No reliable public evidence supports treating aprotinin as a high-growth pharmaceutical ingredient market.

What patents protect aprotinin?

Aprotinin’s core composition-of-matter protection is effectively expired in major markets. The molecule was discovered and commercialized decades ago, placing any original compound patents well beyond ordinary pharmaceutical patent terms.

Current IP value is more likely to arise from:

• specific formulations;
• manufacturing and purification processes;
• source-material controls;
• viral or pathogen-reduction methods;
• container-closure systems;
• combination products;
• administration protocols;
• narrow method-of-use claims.

These rights are unlikely to recreate exclusivity for the core ingredient. A patent search should distinguish expired Trasylol-era patents from later process patents and regulatory exclusivities.

IP category	Commercial significance
Original aprotinin composition claims	Generally expired
Basic intravenous formulation	Likely expired or weak
Manufacturing and purification	Potentially relevant where technically specific
Bovine-source controls	Operational and quality value rather than broad market exclusivity
Method-of-use claims	Potentially relevant but narrow
Combination or delivery claims	Limited unless tied to a differentiated product
Regulatory exclusivity	Not expected to provide a broad current barrier for the legacy molecule

Are there Paragraph IV challenges or Orange Book listings for aprotinin?

Aprotinin is not a conventional current U.S. small-molecule generic-growth opportunity. The main historical product was a biologically derived injectable drug, and the commercial opportunity is constrained more by regulatory status, manufacturing complexity, and market size than by active patent litigation.

The product’s core patent estate is old. Any Paragraph IV challenge would require an identified listed patent and an active reference product against which an abbreviated application could be filed. Publicly visible litigation does not establish a current, broad Paragraph IV campaign around aprotinin.

Orange Book relevance is also limited. The applicable listing status depends on the specific U.S. reference product and current FDA records. Aprotinin should not be analyzed like a blockbuster tablet with multiple active formulation and method-of-use patents.

What manufacturing and IP barriers affect aprotinin?

Manufacturing is a more important barrier than basic molecule patents.

Aprotinin is a protein product with quality attributes affected by:

• biological source material;
• extraction and purification;
• proteolytic degradation;
• aggregation;
• microbial and viral contamination;
• batch-to-batch potency;
• immunogenicity risk;
• cold-chain and stability controls.

A supplier must establish consistent activity, purity, sterility, and source traceability. Animal-derived materials create additional requirements relating to transmissible agents, bovine-origin controls, and regulatory documentation.

These factors can deter low-volume entrants even after patent expiry. The relevant competitive moat is operational rather than classic composition-of-matter exclusivity.

Which companies are challenging or competing with aprotinin?

The most important competitors are not necessarily companies developing new aprotinin products. They are manufacturers of alternative antifibrinolytics and providers of blood-conservation technologies.

The competitive landscape includes:

• generic tranexamic acid manufacturers;
• generic aminocaproic acid manufacturers;
• hospital blood-management programs;
• intraoperative cell salvage suppliers;
• point-of-care coagulation testing providers;
• manufacturers of hemostatic agents and sealants;
• cardiac-surgery drug distributors.

Aprotinin’s commercial recovery would require differentiation against established low-cost alternatives, not merely re-entry into an unoccupied market.

What licensing deals and settlement agreements affect aprotinin?

No major current licensing or patent-settlement structure defines the aprotinin market in the way that settlements define markets for high-value small molecules. Historically, commercial control centered on Bayer’s Trasylol franchise and regional supply arrangements.

Any present licensing opportunity would be more likely to involve:

• manufacturing rights;
• regional distribution;
• recombinant or non-bovine production;
• hospital supply agreements;
• formulation technology;
• regulatory sponsorship.

The absence of a large active patent estate reduces the value of patent licensing. Manufacturing validation, regulatory approvals, and supply continuity would be the principal transaction issues.

What generic launch scenarios exist for aprotinin?

Three launch scenarios are commercially plausible:

Scenario	Probability profile	Market effect
Low-cost conventional injectable entry	Limited by small demand and regulatory burden	Could reduce price but may not expand use
Premium controlled-use product	Requires strong safety and quality positioning	Could capture selected high-risk CABG patients
Recombinant or improved-source aprotinin	Technically differentiated but costly	Could address animal-origin and consistency concerns

The most credible opportunity is a controlled hospital product supported by reliable manufacturing and clear patient-selection criteria. A broad generic launch would face limited demand and aggressive substitution from tranexamic acid.

How strong is the aprotinin patent estate?

The core patent estate is weak because the molecule and original product concepts are old. The broader product franchise may still have defensible know-how in manufacturing, quality control, sourcing, and regulatory documentation.

Estate component	Strength
Core molecule	Low
Historical brand protection	Expired or commercially irrelevant
Basic formulation	Low
Manufacturing know-how	Moderate where proprietary and difficult to reproduce
Animal-source controls	Moderate operational barrier
New use claims	Potentially narrow
Market exclusivity	Low absent a new regulatory designation

Aprotinin is therefore better analyzed as a regulated manufacturing and supply opportunity than as an active patent-protected franchise.

What is the investment outlook for aprotinin?

The investment case is defensive and niche. Upside depends on reliable supply, regulatory acceptance, and adoption in carefully selected high-risk cardiac-surgery patients. The downside is driven by adverse-event exposure, low market volume, generic competition, and physician preference for tranexamic acid.

Revenue growth would likely require one of four changes:

1. evidence supporting a narrowly defined high-benefit patient population;
2. a differentiated recombinant or safer-source product;
3. expansion into a new approved indication;
4. a supply disruption affecting competing antifibrinolytics.

Absent those developments, the expected trajectory is stable-to-declining niche revenue rather than a return to pre-2007 blockbuster economics.

Key Takeaways

• Aprotinin is an active pharmaceutical ingredient, not a conventional pharmaceutical excipient.
• Its historic commercial product was Trasylol, used primarily in cardiac surgery.
• Regulatory safety concerns caused a major market collapse after the 2007 withdrawal.
• Restricted European reintroduction did not restore the former sales base.
• Tranexamic acid and aminocaproic acid are the principal competitive alternatives.
• Core composition patents are effectively expired in major jurisdictions.
• Manufacturing, source control, protein quality, and regulatory compliance are more important barriers than basic patent rights.
• Public standalone revenue data are limited, but the current market is best characterized as small, institutional, and low-growth.
• A new aprotinin product would need a differentiated safety, sourcing, or manufacturing proposition to support commercial investment.

FAQs

Is aprotinin still commercially available?

Aprotinin remains a restricted hospital medicine in selected jurisdictions, but availability depends on national authorization, supplier status, and institutional formulary decisions.

Can aprotinin be used as a pharmaceutical excipient?

No. Aprotinin has direct pharmacologic activity and is classified as an active drug substance when used therapeutically.

Is aprotinin a biologic?

Aprotinin is a protein drug, but its regulatory classification depends on the jurisdiction and product pathway. It is not analyzed commercially like a modern monoclonal antibody or biosimilar market.

Does aprotinin have biosimilar competition?

There is no broad biosimilar market comparable to that for monoclonal antibodies. Any follow-on product would face protein characterization, manufacturing, regulatory, and clinical comparability requirements.

What is the largest commercial risk for an aprotinin manufacturer?

The largest risks are restricted clinical use, safety-related liability, low market volume, and substitution by inexpensive generic antifibrinolytics.

References

1. European Medicines Agency. (2012). European Medicines Agency recommends lifting suspension of aprotinin. https://www.ema.europa.eu
2. Fergusson, D. A., Hébert, P. C., Mazer, C. D., Fremes, S., MacAdams, C., Murkin, J. M., et al. (2008). A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. New England Journal of Medicine, 358(22), 2319-2331. https://doi.org/10.1056/NEJMoa0802395
3. Bayer AG. (2007). Annual report 2006. Bayer Investor Relations. https://www.bayer.com
4. U.S. Food and Drug Administration. (2007). FDA issues early communication about safety of Trasylol. https://www.fda.gov
5. U.S. Food and Drug Administration. (2021). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/agext/index.cfm